EICHORPublic-registry trials using Tocilizumab that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
| Trial | Sponsor | Condition | Phase | Sites |
| A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) | Merck Sharp & Dohme LLC | Chronic Lymphocytic Leukaemia | PHASE2 | 0 |
| First FDA approval | ACTEMRA — January 2010 (application BLA125276, currently held by GENENTECH) |
| Approval timeline | ACTEMRA 2010 (GENENTECH) → TOFIDENCE 2023 (BIOGEN MA) → TYENNE 2024 (FRESENIUS KABI USA) → AVTOZMA 2025 (CELLTRION INC) |
| Also known as | ACTEMRA · TOFIDENCE · TYENNE · AVTOZMA |
| Approved applications | 7 — a multi-source (generic) drug |
| Forms & routes | Injectable · Subcutaneous, Injection, Intravenous, Intravenous, Subcutaneous, Iv (Infusion) |
| Registry-wide use | 615 registered studies all-time · 74 currently recruiting |
Sources: FDA Drugs@FDA and ClinicalTrials.gov, public records. The application holder shown is the current holder, which may differ from the original developer.
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Trialed alongside
Other Chronic Lymphocytic Leukaemia drugs
← Eichor home · All tracked trials · Chronic Lymphocytic Leukaemia studies · Weekly briefs
